Research analysts at TD Cowen assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating on the stock.
A number of other analysts also recently issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a report on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock. Guggenheim initiated coverage on Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 price objective for the company.
Read Our Latest Stock Analysis on SION
Sionna Therapeutics Price Performance
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
- Five stocks we like better than Sionna Therapeutics
- What is a SEC Filing?
- Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?
- Where to Find Earnings Call Transcripts
- Is the S&P 500 Ready to Rally? A $1.8M Bet on SPY Says Yes
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Consumer Spending Is Slowing—But These Stocks Will Still Thrive
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
